|
- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30441
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
本帖最后由 风雨不动 于 2012-4-14 15:32 编辑
<http://www.infectioncontroltoday.com/news/2011/03/scientists-develop-new-instrument-for-analyzing-viruses.aspx>
Scientists Develop New Instrument for Analyzing Viruses
Scientists in Israel and California have developed an instrument for rapidly
analyzing molecular interactions that take place viruses and the cells they
infect. By helping to identify interactions between proteins made by viruses
like HIV and hepatitis and proteins made by the human cells these viruses
infect, the device may help scientists develop new ways of disrupting these
interactions and find new drugs for treating those infections.
According to Doron Gerber, a professor at Bar Ilan University in Ramat Gan, the
PING system (Protein Interaction Network Generator) can be used to examine
thousands of potential interactions at a time, and it detects them at a
sensitivity 100- to 1,000-time greater than current methods. Gerber developed
PING with collaborators at Stanford University, and he described the technology
at the 55th annual Biophysical Society meeting in Baltimore.
When a virus infects a human cell, it hijacks the machinery of that cell,
recruiting certain host proteins and subverting them to the task of
manufacturing new viral particles. This feature of viral biology has made viral
infections notoriously difficult to treat, as therapies must specifically target
the virus without harming the cell.
One approach that has been successful is to identify key interactions between
viral and host proteins, which can then serve as targets for new drugs. For
example, the HIV drug Fuzeon works by blocking a viral protein from attaching to
proteins on the surface of immune system cells, barring entry to the cell.
Like many antivirals, Fuzeon is used in combination with other drugs in a
"cocktail." This is because, like most viruses, HIV mutates rapidly, acquiring
resistance to individual drugs. Therefore, the need for new antiviral drugs is
constant and ongoing.
Using PING, the Israeli and California scientists identified novel cellular
partners for proteins from hepatitis C and hepatitis D. "And we can now use the
same system to screen for inhibitors," says Gerber, who adds that new treatments
are urgently needed for hepatitis C, for which only one treatment exists that
works in only half the patient population.
Because PING employs microfluidics, very small samples can be used; gathering
enough material has been a particular challenge with existing methods.
The research was funded by the NIH Pioneer grant.
(6.合.彩).足球.篮球...各类投注开户下注
第一投注.现金网:招代理年薪10万以上:6668.cc |
|
发表于 2011-3-16 06:24
